PDF herunterladen
Semin Thromb Hemost 2020; 46(07): 781-784
DOI: 10.1055/s-0040-1712156
Commentary

Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy—Either, Neither, or Both

Marcel Levi
1   Department of Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom
2   NIHR UCLH/UCL Biomedical Research Centre, London, United Kingdom
,
Jecko Thachil
3   Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Patients with severe coronavirus disease 2019 (COVID-19) infections manifest coagulation abnormalities that have been associated with respiratory deterioration and death.[1] [2] In addition, many patients with severe COVID-19 infections develop venous thromboembolism, which seems to be related to the coagulopathy.[3] It has also been suggested that undiagnosed pulmonary embolism contributes to a sudden deterioration of pulmonary oxygen exchange that is sometimes seen in patients with COVID-19 infections.[4] [5]

The coagulopathy associated with COVID-19 mimics other systemic coagulopathies that are regularly seen in severe infections, such as disseminated intravascular coagulation (DIC) or thrombotic microangiopathy (TMA).[6] [7] [8] However, at the same time, the clinical and laboratory characteristics of the coagulation changes in COVID-19 are distinctly different from the common presentation of these conditions.



Publikationsverlauf

Artikel online veröffentlicht:
08. Juni 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
    Google Scholar
  • 2 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
    CrossrefPubMedGoogle Scholar
  • 3 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; (e-pub ahead of print) DOI: 10.1016/j.thromres.2020.04.013.
    CrossrefPubMedGoogle Scholar
  • 4 Yuanliang X, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiology: Cardiothoracic Imaging 2020; 2 (02) e200067 (e-pub ahead of print) DOI: 10.1148/ryct.2020200067.
    CrossrefPubMedGoogle Scholar
  • 5 Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association?. Eur Heart J 2020; (e-pub ahead of print) DOI: 10.1093/eurheartj/ehaa254.
    CrossrefPubMedGoogle Scholar
  • 6 Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2: 16037
    CrossrefPubMedGoogle Scholar
  • 7 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341 (08) 586-592
    CrossrefPubMedGoogle Scholar
  • 8 George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371 (07) 654-666
    CrossrefPubMedGoogle Scholar
  • 9 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 10 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020; 120 (05) 876-878
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020; 506: 145-148
    CrossrefPubMedGoogle Scholar
  • 12 Brogaard Larsen J, Pasalic L, Hvas AM. Platelets in coronavirus disease. Semin Thromb Hemost 2020; 46 (07) 823-825
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 13 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 46: 823-825
    PubMedGoogle Scholar
  • 14 Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30 (04) 753-756
    CrossrefPubMedGoogle Scholar
  • 15 Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med 2020; (e-pub ahead of print) DOI: 10.1515/cclm-2020-0272.
    CrossrefPubMedGoogle Scholar
  • 16 Levi M. Platelets in critical illness. Semin Thromb Hemost 2016; 42 (03) 252-257
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 17 Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diagnosis. Expert Rev Hematol 2018; 11 (08) 663-672
    CrossrefPubMedGoogle Scholar
  • 18 Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109 (22) 2698-2704
    CrossrefPubMedGoogle Scholar
  • 19 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (05) 1327-1330
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 20 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; (e-pub ahead of print) DOI: 10.1111/jth.14817.
    CrossrefPubMedGoogle Scholar
  • 21 Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 2014; 164 (06) 759-766
    CrossrefPubMedGoogle Scholar
  • 22 Fox SE, Atmakbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and cardiac pathologyin Covid-19: the first autopsy series from New Orleans. MedRxiv 2020; (e-pub ahead of print) DOI: 10.1101/2020.04.06.20050575.
    CrossrefPubMedGoogle Scholar
  • 23 Levi M, Scully M, Singer M. The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost 2018; 16 (04) 646-651
    CrossrefPubMedGoogle Scholar
  • 24 Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015; 113 (04) 708-718
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 25 Gralinski LE, Bankhead III A, Jeng S. et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. MBio 2013; 4 (04) e00271-e13
    CrossrefPubMedGoogle Scholar
  • 26 Liu ZH, Wei R, Wu YP. et al. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. Biomed Environ Sci 2005; 18 (04) 260-264
    PubMedGoogle Scholar
  • 27 Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002; 67 (01) 92-98
    CrossrefPubMedGoogle Scholar
  • 28 Bellingan GJ. The pulmonary physician in critical care * 6: the pathogenesis of ALI/ARDS. Thorax 2002; 57 (06) 540-546
    CrossrefPubMedGoogle Scholar
  • 29 Glas GJ, Van Der Sluijs KF, Schultz MJ, Hofstra JJ, Van Der Poll T, Levi M. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemost 2013; 11 (01) 17-25
    CrossrefPubMedGoogle Scholar